Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses (SJ-96-0025)





Technology Name
(St. Jude Reference #)
Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses (SJ-96-0025)
Description Mixtures of at least 4 to about 10,000 different recombinant viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions for treatment of HIV infection (US 6,723,558).
Polyenv vaccines are provided that comprise mixtures of at least 4 to about 10,000 different recombinant viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using such polyenv vaccines and viruses, including the use of the polyenv vaccine, in live, attenuated or inactivated form, for prophylaxis or treatment of HIV infection. The viral vaccines of the invention are optimally combined with a recombinant HIV env booster, or a recombinant HIV env gene DNA priming or boosting vaccine.
Keywords HIV, virus, vaccine, AIDS
Granted Patents or Published Applications US Patents 6,086,891; 6,723,558; 5,741,492; and 5,846,546; multiple foreign
Related Scientific References  
Licensing Opportunities We are currently seeking a partner to commercialize this vaccine.
   

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: December 2013